How These Biotech Stocks are Faring? -- Immunomedics, Sequenom, INSYS Therapeutics, and Regulus Therapeutics

Sep 08, 2016, 07:59 ET from Chelmsford Park SA

NEW YORK, September 8, 2016 /PRNewswire/ --

Biotechnology is well known for cycling between booms and busts, making it both an interesting and intimidating space to navigate. It is a place where investors either come out soaring to the top or the other way around. This morning, directs its attention to the following equities: Immunomedics Inc. (NASDAQ: IMMU), Sequenom Inc. (NASDAQ: SQNM), INSYS Therapeutics Inc. (NASDAQ: INSY), and Regulus Therapeutics Inc. (NASDAQ: RGLS).  Register now and get full and free access to our downloadable research reports on these stocks at:


Shares in Morris Plains, New Jersey headquartered Immunomedics Inc. ended Wednesday's session at $2.86, climbing 1.06%. The stock recorded a trading volume of 501,882 shares. The Company's shares are trading 8.94% above their 50-day moving average and 1.77% above their 200-day moving average. Moreover, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have a Relative Strength Index (RSI) of 56.12.

On August 17th, 2016, Immunomedics reported that total revenues for Q4 ended June 30th, 2016, were $0.9 million, compared to $2.4 million for the same quarter last year. Net loss attributable to stockholders was $15.9 million, or $0.17 per basic and diluted share, for Q4 FY16, compared with net loss attributable to stockholders of $12.4 million, or $0.13 per basic and diluted share, for Q4 FY15. Access our complete research report on IMMU for free at:


San Diego, California headquartered Sequenom Inc.'s stock closed the day flat at $2.39 with a three months average volume of 2.13 million shares traded. The Company's shares have advanced 0.84% in the last month, 113.39% over the previous three months, and 45.73% on an YTD basis. The stock is trading 36.52% above its 50-day moving average and 61.58% above its 200-day moving average. Additionally, shares of Sequenom, which develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the US and internationally, have an RSI of 80.18.

On September 07th, 2016, Laboratory Corp. of America® Holdings announced the successful completion of the offering period for the cash tender offer by its direct wholly owned subsidiary, Savoy Acquisition Corp., for all outstanding shares of common stock of Sequenom. The depositary for the tender offer has advised LabCorp that, as of 12:01 a.m. ET on September 7th, 2016, the expiration of the offering period, stockholders of Sequenom had validly tendered 82,901,857 Shares during the offering period, representing an aggregate of approximately 69% of Sequenom's outstanding shares of common stock as of such time, which shares are sufficient to have met the minimum condition of the offer and to enable the Merger to occur under Delaware law without a vote of Sequenom's stockholders. The complimentary research report on SQNM can be downloaded at:

INSYS Therapeutics  

On Wednesday, shares in Chandler, Arizona headquartered INSYS Therapeutics Inc. recorded a trading volume of 1.22 million shares, which was higher than their three months average volume of 781,790 shares. The stock ended the day 5.22% higher at $15.71. The Company's shares are trading above their 50-day moving average by 0.72%. Furthermore, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 49.84.

On August 25th, 2016, Reuters reported that the Illinois attorney general sued Insys Therapeutics, accusing it of deceptively marketing and selling an addictive fentanyl-based medication, intended to treat cancer pain, to doctors for off-label uses. As per the article, Attorney General Lisa Madigan, whose office is investigating other opioid manufacturers for similar practices, said the lawsuit seeks to bar Insys from selling its products in Illinois and impose financial penalties on the company. Register for free on and get access to the latest PDF format report on INSY at:

Regulus Therapeutics  

San Diego, California headquartered Regulus Therapeutics Inc.'s stock jumped 4.60%, finishing yesterday's session at $3.41 with a total trading volume of 323,303 shares. Shares of the Company, which focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the US, are trading below their 50-day moving average by 0.96%. The stock has an RSI of 51.05.

On August 2nd, 2016, Regulus reported that revenue was $0.5 million and $1.0 million for the three and six months ended June 30th, 2016, respectively, compared to $3.8 million and $8.0 million, respectively, for the same periods in 2015. The company's net loss was $21.1 million, or $0.40 per share, and $42.3 million, or $0.80 per share, for the three and six months ended June 30th, 2016, respectively, compared to a net loss of $21.0 million, or $0.41 per share, and $35.5 million, or $0.70 per share, for the same periods in 2015. Download your free research report on RGLS at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA